Skip to content
Biotechnology, Medical Health Aged Care

New Medicines Manufacturing Innovation Centre opens: Monash accelerates medical innovation and development of life-saving treatments

Monash University 2 mins read

New Medicines Manufacturing Innovation Centre opens: Monash accelerates medical innovation and development of life-saving treatments 

 

Victorian Deputy Premier and Minister for Medical Research the Hon Ben Carroll today officially opened the newly built Medicines Manufacturing Innovation Centre (MMIC) within the heart of the Monash Technology Precinct, Clayton. 

 

Funded through an $8.58 million investment from the Victorian Higher Education State Investment Fund and $4 million from Monash University, MMIC’s expansion to Clayton builds on the Centre’s work based at the Monash Institute of Pharmaceutical Sciences (MIPS) in Parkville to provide further opportunities for innovation across medicine formulation, resolving manufacturing process challenges and building supply of highly-skilled, industry ready candidates for the workforce. 

 

Minister Carroll also announced a grant awarded to MMIC by the Cumming Global Centre for Pandemic Therapeutics (Cumming Global Centre). The grant will fund the development of a potential new therapeutic agent for the treatment of respiratory infections and inflammation, with the aim to help safeguard the community against both existing and future viruses.

 

Director of MMIC, Professor Michelle McIntosh said the Centre’s expansion to Clayton will deliver far-reaching benefits to the Victorian community.

 

“This new facility represents a significant advancement in Victoria’s research commercialisation opportunities. Our team of dedicated pharmaceutical scientists are committed to driving forward the end-to-end development of a range of medicines using state-of-the-art technology, from laboratory-scale projects right through to local manufacture of medicines for clinical trials,” Professor McIntosh said.

 

“We’re also thrilled to have Cumming Global Centre’s Professor Sharon Lewin join us for the MMIC launch. Fostering collaboration between research institutes is central to MMICs mission, and we are excited to be working with Professor Lewin and her team to progress a new treatment for respiratory viruses and further strengthen Australia’s resilience to future health emergencies,” Professor McIntosh said. 

 

Inaugural Director of the Cumming Global Centre, Melbourne Laureate Professor Sharon Lewin congratulated Professor McIntosh on the grant and said she looks forward to seeing the project come to fruition.

 

“In a globally competitive process, Professor McIntosh’s exploration of an innovative delivery system to treat future respiratory viruses stood out for both scientific excellence and its alignment to the Centre’s mission to advance the science behind therapeutics for pathogens of pandemic potential,” Professor Lewin said. 

Monash University Vice-Chancellor and President Professor Sharon Pickering said the permanent MMIC facility is an important new addition to the Monash Technology Precinct – a world class hub of research, industry, innovation and talent that is part of Victoria’s largest employment precinct outside the Melbourne CBD.

“This new facility will further strengthen the research and development capability of the Monash Technology Precinct innovation ecosystem, joining world-leading research and technology organisations such the CSIRO, the Melbourne Centre for Nanofabrication, the Victorian Heart Hospital and the soon-to-be completed Moderna manufacturing facility.

 

“By being located in the world-class Monash Technology Precinct, the MMIC will provide our researchers, precinct partners and local and international companies the opportunity to develop, test and scale-up new medicines here in Australia without going off-shore.”

MMIC Clayton is a purpose designed and built facility including laboratory and office space, co-located with the Australian Synchrotron in the heart of the Monash Technology Precinct, promoting further economic opportunities and growing employment.

ENDS

 


Contact details:

Kate Carthew

0438 674 814

[email protected] 

Media

More from this category

  • Medical Health Aged Care
  • 15/08/2026
  • 07:02
Optimi Health Corp.

Optimi Health Establishes Discretionary Equity Facility

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.Sales under the ELOC are at the…

  • Medical Health Aged Care, Research Development
  • 14/08/2026
  • 08:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG opens 2026 Fund for New Research Grants to accelerate the next generation of gynaecological cancer research

MEDIA RELEASE Friday, 14 August 2026 ANZGOG opens 2026 Fund for New Research Grants to accelerate the next generation of gynaecological cancer research The Australia New Zealand Gynaecological Oncology Group (ANZGOG) has today opened applications for its 2026 Fund for New Research Grant Program, supporting researchers to investigate promising ideas and generate the evidence needed to progress larger studies and future clinical trials. Supported by significant contributions from ANZGOG donors, the 2026 program will fund four priority research areas, with grants ranging from $50,000 to $100,000: Endometrial cancer focused surgical study – one grant of up to $55,000 Leiomyosarcoma focused…

  • Animal Animal WelfareRights, Medical Health Aged Care
  • 13/08/2026
  • 10:30
Monash University

Monash experts: Avian Influenza

Monash University experts are available to discuss the spread of H5 bird flu and its implications across native bird populations, agriculture, farming and general preparedness. Professor Anne Peters, specialist in the behaviour ecology and conservation of birds, Deputy Head of School of Biological Sciences,Monash University Contact details: +61 3 9903 4840 or [email protected] Read more Analysis and Opinion from Professor Peters The following can be attributed to Professor Peters: “Regarding theflu being detected in silver gulls, this is obviously very concerning. These seagulls are what many people know as the 'fish & chip' gull, i.e. they are common, range widely,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.